Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAnna CandoniPDPierre‐Yves DumasMRMenno Van Roosmalen

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 79.6% one-year survival in Acute Myeloid Leukemia patients treated with azacitidine and Ivosidenib, indicating the importance of real-world evidence.

Key Points

  • 79.6% one-year overall survival reported in patients treated with azacitidine and ivosidenib.
  • Among 23 patients, median follow-up time was 21.2 months, revealing promising outcomes.
  • Retrospective cohort study utilized real-world evidence from the TriNetX Dataworks Platform in the USA.
  • Findings support treatment utility, but further real-world evidence generation is warranted.

Cite This Study

Candoni et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da59https://doi.org/10.1182/blood-2025-3401
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo2025 · 1 citations
  2. 2Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study2025
  3. 3Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)2025 · 3 citations
  4. 4A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress2025
  5. 5Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation2025 · 2 citations